Antiviral treatment of chronic hepatitis B virus infection with recombinant leukocyte A interferon.

概要

論文の詳細を見る
Large doses of recombinant leukocyte A interferon (rIFN-αA) were administered to 20 patients with hepatitis B e antigen (HBeAg) positive chronic hepatitis B to study its efficacy and safety. The first group of 5 patients received a constant dose of 36×106u/day for consecutive 28 days. When it was well tolerated, the 2nd, 3rd and 4th groups, 5 patients each, received 50, 72 and 100 million units/day, respectively. All 20 patients completed the 28-day treatment.<BR>DNA-polymerase activity in the serum turned negative in 14 out of 18 cases (78%) during the treatment and it remained negative in only 5 cases 4 weeks after the treatment. Inhibition of serum DNA-p activity during the treatment was compared among the 4 groups and we found the extent of suppressed DNA-p activity almost the same among them.<BR>Prednisolone withdrawal was combined with rIFN-αA in 5 patients. Three patients treated with such combination became seronegative for HBeAg 6 months after the treatment, whereas only one of 15 with rIFN-αA alone turned seronegative.<BR>Major side effects included fever, fatigue, hair loss, leukocytopenia and thrombocytopenia, and all of them disappeared in due time.
社団法人日本肝臓学会の論文